Human safety, tolerability, and pharmacokinetics of a novel broad-spectrum oral antiviral compound, molnupiravir, with activity against SARS-CoV-2

WP Painter, W Holman, JA Bush, F Almazedi, H Malik… - medrxiv, 2020 - medrxiv.org
… : (i) to determine the safety and tolerability of single and multiple ascending doses of
molnupiravir, and (ii) to assess the effect of food on the pharmacokinetics of molnupiravir and EIDD-…

[HTML][HTML] Safety and efficiency of molnupiravir for COVID-19 patients with advanced chronic kidney disease

I Dufour, A Devresse, A Scohy, C Briquet… - Kidney research and …, 2023 - ncbi.nlm.nih.gov
molnupiravir as an oral treatment for COVID-19 in nonhospitalized adults (MOVe-OUT) showed
good efficacy… report on the efficacy and safety of molnupiravir in advanced CKD patients. …

Safety and Effectiveness of Molnupiravir in Japanese Patients with COVID-19: Final Report of Post-Marketing Surveillance in Japan

S Shinozaki, A Watanabe, M Kimata… - Infectious Diseases and …, 2024 - Springer
… First, because of the noninterventional, single-arm observational design of this survey, we
could not statistically compare the safety and effectiveness of molnupiravir treatment with other …

Safety and Effectiveness of Molnupiravir (LAGEVRIO®) Capsules in Japanese Patients with COVID-19: Interim Report of Post-marketing Surveillance in Japan

M Kimata, A Watanabe, Y Yanagida… - Infectious diseases and …, 2023 - Springer
molnupiravir in Japan, the actual administration status, safety, … molnupiravir in daily clinical
practice use in Japan supports the safety and effectiveness profile of molnupiravir in treating

[HTML][HTML] Effectiveness and adverse events of nirmatrelvir/ritonavir versus molnupiravir for COVID-19 in outpatient setting: multicenter prospective observational study

JJ Park, H Kim, YK Kim, SS Lee, E Jung… - Journal of Korean …, 2023 - ncbi.nlm.nih.gov
treatment for coronavirus disease 2019 (COVID-19) is the combination of nirmatrelvir and
ritonavir; whereas molnupiravir is used as an alternative treatment for … By contrast, molnupiravir

Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19

JR Arribas, S Bhagani, SM Lobo, I Khaertynova… - NEJM …, 2022 - evidence.nejm.org
… clinical efficacy of molnupiravir in the hospitalized participants studied: sustained recovery
rates through day 29, the primary efficacy … who had not received treatment with remdesivir or …

Real-world clinical outcomes of treatment with molnupiravir for patients with mild-to-moderate coronavirus disease 2019 during the Omicron variant pandemic

Y Suzuki, Y Shibata, H Minemura, T Nikaido… - Clinical and …, 2023 - Springer
… It is unclear whether molnupiravir has a beneficial effect on … We here evaluated the efficacy
of molnupiravir in patients with … admission was compared between molnupiravir users (n = …

Nirmatrelvir/ritonavir and molnupiravir in the treatment of mild/moderate COVID-19: results of a real-life study

I Gentile, R Scotto, N Schiano Moriello, B Pinchera… - Vaccines, 2022 - mdpi.com
… 10 days in the molnupiravir group, p < 0.01. We recorded … treated with molnupiravir terminated
treatment due to ADRs. In conclusion, in a population of mostly vaccinated patients treated

Efficacy and safety of antiviral treatments for symptomatic COVID-19 outpatients: Systematic review and network meta-analysis

M Zur, T Peselev, S Yanko, V Rotshild, I Matok - Antiviral Research, 2023 - Elsevier
… the efficacy and safety of three new antivirals (remdesivir, nirmatrelvir/ritonavir, and
molnupiravir) for treating mild to … In contrast, molnupiravir showed the lowest efficacy. Remdesivir …

Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic

S Khiali, E Khani, SB Rouy… - Future Microbiology, 2022 - Taylor & Francis
… trials of molnupiravir in … safety profile of molnupiravir; however, given its possible genotoxic
effects, further trials are required to confirm the long-term efficacy and safety of molnupiravir